Personalized benefit‐risk assessments combining clinical trial and real‐world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy
- 7 March 2019
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (4) , 443-451
Abstract
Purpose: Quantitative benefit‐risk (B‐R) assessments are used to characterize treatment by combining key benefits and risks into a single metric but have historically been done for the “average” patient. Our aim was to conduct an individualized assessment for the oral antiplatelet vorapaxar by combining trial and real‐world data to further personalize the treatment profiles.Methods: Using linked UK health care databases, we developed risk prediction equations for key ischemic and bleeding events using Cox proportional hazards models. Trial hazard ratios, relative to placebo, were applied to baseline risk estimates to compute expected attributable risks, summed to derive a per‐patient net clinical benefit (NCB). High risk subgroups were defined a priori, and Gaussian mixture models (GMM) were fit to characterize the NCB distribution and identify subgroups with similar NCBs.Results: NCB was consistently positive for all subgroups, likely due to the outcome correlation, and would remain positive with a 12‐fold increase in bleeding risk. GMMs identified three distinct NCB subgroups. Compared with the middle/lower NCB subgroups, those with a higher NCB tended to be older, female, and have higher CV disease burden.Conclusions: Personalized B‐R assessments are feasible and clinically valuable and can be used to better predict who would benefit most from therapy.Keywords
Funding Information
- Merck
This publication has 21 references indexed in Scilit:
- Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AFInternational Journal of Cardiology, 2018
- Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivorsEuropean Heart Journal, 2017
- Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk AssessmentMedical Decision Making, 2015
- Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplastyVascular Health and Risk Management, 2014
- Data Resource Profile: Cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER)International Journal of Epidemiology, 2012
- Multicriteria benefit–risk assessment using network meta-analysisJournal of Clinical Epidemiology, 2012
- A stochastic multicriteria model for evidence‐based decision making in drug benefit‐risk analysisStatistics in Medicine, 2011
- Individualizing the risks and benefits of postmenopausal hormone therapyMenopause, 2008
- What is the harm-benefit ratio of Cox-2 inhibitors?International Journal of Epidemiology, 2008
- Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosisJournal of Clinical Epidemiology, 2004